Last Updated: August 16, 2026

Details for Patent: 12,281,113


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,281,113 protect, and when does it expire?

Patent 12,281,113 protects KRAZATI and is included in one NDA.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: 12,281,113
Title:Crystalline forms of a KRas G12C inhibitor
Abstract:The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.
Inventor(s):Patricia Andres, Samuel Andrew, Cheng Yi Chen, Susana Del Rio Gancedo, Tawfik Gharbaoui, Jennifer Nelson
Assignee: Mirati Therapeutics Inc
Application Number:US18/782,879
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 12,281,113

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol KRAZATI adagrasib TABLET;ORAL 216340-001 Dec 12, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,281,113

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2021340716 ⤷  Start Trial
Brazil 112023004569 ⤷  Start Trial
Canada 3190944 ⤷  Start Trial
Chile 2023000693 ⤷  Start Trial
China 116601151 ⤷  Start Trial
Colombia 2023004141 ⤷  Start Trial
European Patent Office 4210833 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.